SCHEMBL5213780

SCHEMBL5213780

CCOP(=O)(Cc1ccc(NC(=O)CCc2oc(N3CCOCC3)nc2-c2ccc(Cl)cc2)cc1)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
MAPK1 P28482 2/20 0.42
PIK3CA P42336 3/20 0.40
PIK3CG P48736 3/20 0.40
MTOR P42345 2/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 1/20 0.40
MCHR1 Q99705 2/20 0.40
CHRM1 P11229 1/20 0.40
HTR2A P28223 1/20 0.40
PARP3 Q9Y6F1 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PPARG P37231 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 2/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207380 0.92 LMNA (0.45) MAPTMAPK1KMT2AMCHR1CHRM1
SCHEMBL5213028 0.89 CHRM1 (0.41) MAPTMAPK1KMT2AMCHR1CHRM1
SCHEMBL5207021 0.85 MAPT (0.44) MAPTMAPK1KMT2AALDH1A1MCHR1
SCHEMBL5212147 0.85 MAPT (0.39) MAPTMAPK1KMT2AMCHR1CHRM1
SCHEMBL5211940 0.84 MAPT (0.45) MAPTMAPK1KMT2AALDH1A1MCHR1
SCHEMBL5210390 0.83 MAPT (0.41) MAPTMAPK1KMT2AMCHR1CHRM1
SCHEMBL5214638 0.83 MAPT (0.41) MAPTMAPK1KMT2AMCHR1CHRM1
SCHEMBL5207465 0.83 MAPT (0.44) MAPTMAPK1KMT2AALDH1A1MCHR1
SCHEMBL5213773 0.83 PIK3CA (0.41) MAPTMAPK1PIK3CAPIK3CGMTOR
SCHEMBL5212800 0.82 MAPT (0.37) MAPTMAPK1KMT2AMCHR1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US claimed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US claimed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP claimed
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPT 3958/4885MAPK1 1553/4885PIK3CA 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.